Friday, June 25, 2010

Nestin as a Marker for Astrocytomas

I recently highlighted the growing parade of pubs referencing use of our reagents for Cancer Research.

I would like to add a new one. Angogenesis of Astrocytomas show stem like properties. This makes our Nestin Antibodies excellent markers.

J H Tchaicha, A K Mobley, M G Hossain, K D Aldape and J H McCarty. A mosaic mouse model of astrocytoma identifies αvβ8 integrin as a negative regulator of tumor angiogenesis. Oncogene , (7 June 2010) doi:10.1038/onc.2010.199...chicken anti-Nestin IgY (Neuromics, Edina, MN, USA)...

Abstract: Angiogenesis involves a complex set of cell–cell and cell–extracellular matrix (ECM) interactions that coordinately promote and inhibit blood vessel growth and sprouting. Although many factors that promote angiogenesis have been characterized, the identities and mechanisms of action of endogenous inhibitors of angiogenesis remain unclear. Furthermore, little is known about how cancer cells selectively circumvent the actions of these inhibitors to promote pathological angiogenesis, a requisite event for tumor progression. Using mosaic mouse models of the malignant brain cancer, astrocytoma, we report that tumor cells induce pathological angiogenesis by suppressing expression of the ECM protein receptor αvβ8 integrin. Diminished integrin expression in astrocytoma cells leads to reduced activation of latent TGFβs, resulting in impaired TGFβ receptor signaling in tumor-associated endothelial cells. These data reveal that astrocytoma cells manipulate their angiogenic balance by selectively suppressing αvβ8 integrin expression and function. Finally, these results show that an adhesion and signaling axis normally involved in developmental brain angiogenesis is pathologically exploited in adult brain tumors.

Related Reagents:

Nestin Mouse Monoclonal-Cat#:MO15012

Nestin-Mouse Monoclonal-Cat#:MO15056

Nestin-Goat Polyclonal

Stem Cell Research Reagents

No comments: